Blog

A quiet revolution is reshaping how therapies reach patients — and it’s happening faster than anyone expected. The pharmaceutical industry is experiencing a transformative shift towards Direct-to-Consumer (DTC) models, driven by several legislative and regulatory changes.

Artificial intelligence (AI) has advanced rapidly in its ability to understand language and detect emotion, giving pharmaceutical manufacturers powerful tools to scale and customize patient engagement. But AI on its own can’t deliver the kind of empathetic support patients truly need.

Discover the three essential pillars of rare disease support: medical expertise, community connections, and family engagement. Learn how integrating these elements creates comprehensive support networks for the 1 in 1,500 Americans affected by rare diseases.

Motivated patients are more likely to have better adherence and outcomes. Healthcare providers (HCPs) and families play crucial roles in treatment. Cancer mortality has significantly dropped over time, but nonadherence continues to be a problem. This is particularly so for patients taking oral oncolytics.

Measuring success in any endeavor requires a metric and scale by which to measure. Once this is determined, a method must be developed to determine how a company’s efforts rate.

Biopharma companies offer many forms of support when therapy is initiated. Substantial research indicates people with rare or complex conditions require a more intensive level of support that includes addressing the emotional needs related to their condition.

Biopharma utilizes behavioral science more than ever to understand patients, personalize engagement, and motivate therapy adherence.

The pharmaceutical industry continues to make a clear commitment to pharma patient engagement, and the total market investment is expected to increase more than 15% by 2030, according to Grand View Research.